Patent application number | Description | Published |
20110190422 | Continuously Operated Method for Producing Copolymers - The invention relates to a process for the preparation of copolymer in a continuous mode of operation in a polymerization apparatus, comprising a polymerization reactor having feed lines and an outflow, free radical polymerization initiator, an acid monomer and polyether macromonomer being passed as monomeric starting materials into the polymerization reactor through the feed lines, initiator, monomeric starting materials and copolymer-containing reaction composition thermostated at −20 to +120° C. being present in the polymerization reactor, copolymer-containing reaction composition being discharged from the polymerization reactor through the outflow, the introduction of the polyether macromonomer into the polymerization reactor being effected separately from the acid monomer in a manner such that the polyether macromonomer is mixed with the initiator, monomeric starting materials and copolymer-containing reaction composition in the polymerization reactor and comes into contact with the acid monomer for the first time thereby. | 08-04-2011 |
20120059091 | Continuously Operated Method for Producing Copolymers - The invention relates to a process for the preparation of copolymer in a continuous mode of operation in a polymerization apparatus, comprising a polymerization reactor having feed lines and an outflow, free radical polymerization initiator, an acid monomer and polyether macromonomer being passed as monomeric starting materials into the polymerization reactor through the feed lines, initiator, monomeric starting materials and copolymer-containing reaction composition thermostated at −20 to +120° C. being present in the polymerization reactor, copolymer-containing reaction composition being discharged from the polymerization reactor through the outflow, the introduction of the polyether macromonomer into the polymerization reactor being effected separately from the acid monomer in a manner such that the polyether macromonomer is mixed with the initiator, monomeric starting materials and copolymer-containing reaction composition in the polymerization reactor and comes into contact with the acid monomer for the first time thereby. | 03-08-2012 |
20130253089 | CONTINUOUS PROCESS FOR THE SYNTHESIS OF GRAFT POLYMERS BASED ON POLYETHERS - The invention relates to a continuous process for the preparation of amphiphilic graft polymers, wherein a vinyl ester component (B) composed of vinyl acetate and/or vinyl propionate (B1) and, if desired, a further ethylenically unsaturated monomer (B2), is polymerized in the presence of a polyalkylene oxide (A), a free radical-forming initiator (C) and, if desired, an additive (D), at a mean polymerization temperature at which the initiator (C) has a decomposition half-time of from 1 to 500 min, in at least one tubular reactor segment with a feed side and an outlet side, through which the reaction mixture comprising at least a part of component (A) to (C), and if desired (D), streams, a tubular reactor segment and the use of the inventive amphiphilic graft polymer. The invention further relates to an inventive amphiphilic graft polymer and the use thereof. | 09-26-2013 |
Patent application number | Description | Published |
20090018129 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME - The invention relates to substituted aminopyrazolopyridines according to the general formula (I): | 01-15-2009 |
20090030010 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents - This invention relates to compounds of general formula I | 01-29-2009 |
20090075989 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS - The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, | 03-19-2009 |
20090270381 | Non-steroidal progesterone receptor modulators - The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, | 10-29-2009 |
20110112057 | Sequential administration of 20,20,21,21,21-pentafluoro-17-hydroxy-11Beta-[4-(hydroxyacetyl)phenyl]-19- -nor-17Alpha-pregna-4,9-dien-3-one and one or more progestogens for the treatment of gynaecological disorders - The present invention relates to treatment regimes and combination products of 20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-(hydroxyacetyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one of the formula | 05-12-2011 |
20120094969 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception. | 04-19-2012 |
20120149670 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHOD OF PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception. | 06-14-2012 |
20120184515 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIENE-11-METHYLENE OXYALKYLENE ARYL DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF FOR TREATMENT OF DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene-11-methyleneoxyalkylenearyl derivative of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception. | 07-19-2012 |
20120190660 | 17-HYDROXY-17-PENTAFLUOROETHYL-ESTRA-4,9(10)-DIENE-11-ETHYNYLPHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-ethynylphenyl derivatives of the formula I, in which R | 07-26-2012 |
20120232042 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ACYLOXYALKYLENE PHENYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-13-methyl-17-pentafluoroethyl-11-acyloxyalkylenephenyldodecahydrocyclopenta[a]phenanthren-3-one derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception. | 09-13-2012 |
20120258941 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-aryl derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception. | 10-11-2012 |
20120316145 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-BENZYLIDENE DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, | 12-13-2012 |
20130005697 | Progesterone Receptor Antagonists - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of the formula I with a progesterone antagonising effect and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and also their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular of uterus fibroids (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeding, meningiomas, hormone-dependent breast cancers and troubles associated with the menopause or for monitoring fertility and emergency contraception. | 01-03-2013 |
20130072464 | PROGESTERONE RECEPTOR ANTAGONISTS - The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyomata), endometriosis, heavy menstrual bleeding, meningiomata, hormone-dependent breast cancers and menopause-associated complaints or for fertility control and emergency contraception. | 03-21-2013 |
20140357655 | SPIROINDOLINE DERIVATIVES AS GONADOTROPIN- RELEASING HORMONE RECEPTOR ANTAGONISTS - Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists. | 12-04-2014 |